Kyowa-Amgen Antibody Deal Worth Up To $520 Million
This article was originally published in PharmAsia News
Executive Summary
Kyowa Hakko struck a deal worth as much as $520 million with Amgen to outlicense a monoclonal antibody Amgen will develop first for inflammatory disease indications, the firms said March 5
You may also be interested in...
Kyowa Hakko Kirin Pins Rebound On KW-0761 For Oncology And Allergy Indications
TOKYO - Kyowa Hakko Kirin posted modest gains in its pharmaceutical business at its announcement of interim results as expectation rides on the eventual outcome of KW-0761, a humanized anti-CCR-4 monoclonal antibody being developed by Kyowa for hematological cancer applications in Japan and the U.S. and by licensing partner Amgen in the U.K. for allergy application
Kyowa Hakko Kirin Pins Rebound On KW-0761 For Oncology And Allergy Indications
TOKYO - Kyowa Hakko Kirin posted modest gains in its pharmaceutical business at its announcement of interim results as expectation rides on the eventual outcome of KW-0761, a humanized anti-CCR-4 monoclonal antibody being developed by Kyowa for hematological cancer applications in Japan and the U.S. and by licensing partner Amgen in the U.K. for allergy application
Japanese Kyowa's Antibody Technology Could Mean Cheaper Development Costs For Amgen - Analysts
TOKYO - The size of the up-front payment that Amgen provided Kyowa Hakko Kogyo this week to gain development and commercialization rights to the Phase I humanized monoclonal antibody KW-0761 for most of the world - except Japan, Korea, China and Taiwan - indicates strong interest in the Japanese company's Potelligent technology, experts say